Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: Systematic review and network meta-analysis

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Cohen, A T ^a   Hamilton, M ^b   Mitchell, S A ^c   Phatak, H ^b   Liu, X ^d   Bird, A ^e   Tushabe, D ^f   Batson, S ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b BMS   (United States)

^c Decision Resources Group   (United Kingdom)

^d PFIZER INC   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^f TUSH D UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; ORAL DRUG ADMINISTRATION; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DABIGATRAN; HUMANS; PYRAZOLES; PYRIDINES; PYRIDONES; RIVAROXABAN; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84957558536     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144856     Document Type: Article

References (44)

1. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Archives of Internal Medicine. 2000; 160(6):761-8. Epub 2000/03/29. PMID: 10737275.
2. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1, 626 patients. Haematologica. 2007; 92(2):199-205. PMID: 17296569.
3. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: The Vienna prediction model. Circulation. 2010; 121(14):1630-6. doi: 10.1161/CIRCULATIONAHA.109.925214 PMID: 20351233.
4. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arteriosclerosis, Thrombosis, and Vascular Biology. 2009; 29(3):298-310. doi: 10.1161/ATVBAHA.108.182428 PMID: 19228602.
5. Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: A systematic review. Journal of Medical Economics. 2011; 14(1):65-74. Epub 2011/01/13. doi: 10.3111/13696998.2010. 546465 PMID: 21222564.
6. Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy: The Journal of Human Pharmacology & Drug Therapy. 2009; 29(8):943-53. Epub 2009/07/30. doi: 10. 1592/phco.29.8.943 [pii]. PMID: 19637948.
7. Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol. 2009; 145(3):286-95. Epub 2009/02/19. doi: 10.1111/j.1365-2141.2009.07601.x PMID: 19222476.
8. Lang IM. Chronic thromboembolic pulmonary hypertension-not so rare after all. New England Journal of Medicine. 2004; 350(22):2236-8. Epub 2004/05/28. doi: 10.1056/NEJMp048088 PMID: 15163772.
9. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: The Q-VTE Study Cohort. The American Journal of Medicine. 2013; 126 (9):832 e13-e21. doi: 10.1016/j.amjmed.2013.02.024 PMID: 23830539.
10. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thrombosis and Haemostasis. 2007; 98(4):756-64. PMID: 17938798.
11. Venous thromboembolism in adult hospitalizations-United States, 2007-2009. MMWR Morb Mortal Wkly Rep. 2012; 61(22):401-4. Epub 2012/06/08. doi: mm6122a1 [pii]. PMID: 22672974.
12. Hass B, Pooley J, Harrington AE, Clemens A, Feuring M. Treatment of venous thromboembolism- effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management. Thrombosis Journal. 2012; 10(1):24. Epub 2013/01/02. doi: 10.1186/1477-9560-10-24 PMID: 23276253; PubMed Central PMCID: PMC3554503.
13. National Institute for Health and Care Excellence. CG92: Venous thromboembolism-reducing the risk. 2010. Available: http://guidance.nice.org.uk/CG92 Accessed May 2014.
14. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ, American College of Chest Physicians Antithrombotic T, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):7S-47S. doi: 10.1378/chest.1412S3 PMID: 22315257; PubMed Central PMCID: PMC3278060.
15. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2013; 31(17):2189-204. doi: 10.1200/JCO. 2013.49.1118 PMID: 23669224.
16. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e44S-e88S. doi: 10. 1378/chest.11-2292 PMID: 22315269; PubMed Central PMCID: PMC3278051.
17. Nicolaides A, Fareed J, Kakkar A, Breddin H, Goldhaber S, Hull R, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). International Angiology. 2006; 25(2):101-61. PMID: 16763532.
18. Weitz JI. New oral anticoagulants: A view from the laboratory. American Journal of Hematology. 2012; 87 Suppl 1:S133-S6. doi: 10.1002/ajh.23139 PMID: 22407747.
19. Einstein Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. The New England Journal of Medicine. 2010; 363(26):2499-510. doi: 10.1056/NEJMoa1007903 PMID: 21128814.
20. Einstein-PE Investigators, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. The New England Journal of Medicine. 2012; 366(14):1287-97. doi: 10.1056/NEJMoa1113572 PMID: 22449293.
21. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. The New England Journal of Medicine. 2013; 369(9):799-808. doi: 10.1056/NEJMoa1302507 PMID: 23808982.
22. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129 (7):764-72. doi: 10.1161/CIRCULATIONAHA.113.004450 PMID: 24344086.
23. Hokusai VTE Investigators, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. The New England Journal of Medicine. 2013; 369(15):1406-15. doi: 10.1056/NEJMoa1306638 PMID: 23991658.
24. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. The New England Journal of Medicine. 2009; 361(24):2342-52. doi: 10.1056/NEJMoa0906598 PMID: 19966341.
25. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e419S- 94S. doi: 10.1378/chest.11-2301 PMID: 22315268; PubMed Central PMCID: PMC3278049.
26. National Institute for Health and Care Excellence. The guidelines manual. London: National Institute for Health and Care Excellence; 2009. Available: http://www.nice.org.uk/guidelinesmanual AccessedMay 2014.
27. Dias S, Welton, N.J., Sutton, A.J. & Ades, A.E. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. www.nicedsuorg.uk 2011.
28. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal. 2013; 11(1):21. doi: 10.1186/1477-9560-11-21 PMID: 24053656; PubMed Central PMCID: PMC3850944.
29. Palareti G. Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It. Scientifica. 2012.
30. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis. 2005; 3(4):692-4. doi: 10.1111/j.1538-7836.2005.01204.x PMID: 15842354.
31. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011.
32. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, et al. The epidemiology of venous thromboembolism in the community. Thrombosis and Haemostasis. 2001; 86(1):452-63. Epub 2001/08/07. doi: 01070452 [pii]. PMID: 11487036.
33. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. Journal of Thrombosis and Haemostasis: JTH. 2005; 3(8):1611-7. doi: 10.1111/j.1538-7836.2005.01415.x PMID: 16102026.
34. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal. 2014; 35(43):3033-69, 69a-69k. doi: 10.1093/eurheartj/ehu283 PMID: 25173341.
35. Beyer-Westendorf J, Buller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? Journal of Thrombosis and Haemostasis. 2011; 9 (11):2153-8. doi: 10.1111/j.1538-7836.2011.04507.x PMID: 21920015.
36. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ. 2012; 345:e7498. doi: 10.1136/bmj.e7498 PMID: 23150473; PubMed Central PMCID: PMC3496553.
37. Kang N, Sobieraj DM. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thrombosis Research. 2014; 133(6):1145-51. doi: 10.1016/j. thromres.2014.03.035 PMID: 24713109.
38. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: A systematic review and meta-analysis. Journal of Thrombosis and Haemostasis: JTH. 2014; 12(3):320-8. doi: 10.1111/jth.12485 PMID: 24330006.
39. Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis. 2008; 6(8):1313-8. Epub 2008/06/11. doi: 10.1111/j.1538-7836.2008.03054.x PMID: 18541000.
40. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: A systematic review and metaanalysis. JAMA. 2014; 312(11):1122-35. doi: 10.1001/jama.2014.10538 PMID: 25226478.
41. Mantha S, Ansell J. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. Journal of Thrombosis and Thrombolysis. 2015; 39 (2):155-65. doi: 10.1007/s11239-014-1102-5 PMID: 24989022.
42. Spencer FA, Gore JM, Reed G, Lessard D, Pacifico L, Emery C, et al. Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study. Thrombosis and Haemostasis. 2009; 101(5):878-85. Epub 2009/05/01. doi: 09050878 [pii]. PMID: 19404541; PubMed Central PMCID: PMC2827872.
43. Nieto JA, Camara T, Gonzalez-Higueras E, Ruiz-Gimenez N, Guijarro R, Marchena PJ, et al. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thrombosis and Haemostasis. 2008; 100(5):789-96. Epub 2008/11/08. doi: 08110789 [pii]. PMID: 18989522.
44. Prandoni P, Trujillo-Santos J, Sanchez-Cantalejo E, Dalla Valle F, Piovella C, Pesavento R, et al. Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry. Journal of thrombosis and haemostasis. 2010; 8(11):2575-7. Epub 2010/08/26. doi: 10.1111/j.1538-7836.2010.04039.x PMID: 20735724.